For important risk and disclaimer information, Click here.

Industry

Manufacturing

Company Type

Advanced Materials

Size

$10 Million equity

Investment Type

Equity

For additional information, please contact:
Doug Jendras | Managing Director
(203) 501-7667

Investment Opportunity

Company:  IP3 Technologies, Inc. 

Sector:  Advanced Materials – Science| Engineering | Technology

Capital Raise:   Seeking $10MM in equity financing

Use of Funds

  • Accelerate out-licensing of patent-protected IP
  • Generate scalable royalty revenue streams
  • Position company for a potential NASDAQ listing by 2026

Summary

IP3T is a platform company with a high-value portfolio of advanced materials innovations. The business model focuses on developing and monetizing proprietary IP via strategic licensing agreements, enabling non-dilutive revenue growth and risk-mitigated exposure to high-value verticals. The company aims to deliver institutional-grade returns through royalty income while supporting ESG goals of licensees.

Vision Through Innovation

IP3T drives transformational change through breakthrough science and engineering. Our mission is to bring to market next-generation products that exceed current technological benchmarks and enable sustainable, long-term value creation.

We operate with a clear focus on:

  • Continuous innovation and product optimization
  • Delivering tangible impact across environmental, societal, and economic dimensions
  • Licensing innovations that align with global sustainability and decarbonization targets

A PwC-audited model (excluding RECHECKA and AIVIBA) of our late-stage portfolio demonstrates an XNPV valuation range of $500MM to $750MM (30% discount rate applied).

The Power of Royalty-Driven IP Models

The IP3T model is built around royalty monetization — a strategy with unique benefits:

  • Non-dilutive, revenue-based income generation
  • Minimal exposure to operational risk of licensees
  • Long-term recurring cash flows from patent-protected assets
  • Hedge against inflation: not reliant on input costs
  • High scalability with limited capital expenditure
  • Royalty streams can be capitalized via sales to institutional buyers (e.g., pension or sovereign wealth funds)

Royalty income models offer superior risk-adjusted returns relative to traditional equity or debt-based structures.

Current Portfolio Snapshot

IP3T’s portfolio includes seven differentiated assets across materials engineering, science and technology:

MATERIALS SCIENCE

PATHOSTOP: Antibacterial/antiviral additive; kills 99.99% of pathogens in 30 mins, active for 10 years

SKOSHMARK: In-situ verification material with unique spectral signatures

AIVIBA: Orphan-designated, pre-clinical anti-infective drug candidate

MATERIALS ENGINEERING

HIPPOPAK: Reclosable wide-neck carton for semisolid, solid and viscous consumer goods

INSUHEDRA: Interlocking rigid block material for extreme thermal protection

MATERIALS TECHNOLOGY

SPECIDENT: Long-range surface analysis and specification validation tool

RECHECKA: Non-destructive QA system for brand protection and in-situ product validation

Diversified IP Monetization Strategy

IP3T’s approach ensures scalable, risk-mitigated growth through:

 

  • Licensing IP to large, well-capitalized corporates
  • Targeting multiple verticals for diversified revenue
  • Commercial-ready innovations with minimal capital requirements
  • Continuous innovation to replenish IP pipeline
  • Layering of new and existing royalties for compounding effect

 

This strategy supports a structurally advantaged business model focused on consistent cash generation and high-margin scalability.

Management Team

Henry Guy StevensChairman & Director
35+ years in R&D and commercialization with over 200 patents across packaging, logistics, consumer products, and medical devices. Proven track record in IP origination, cross-jurisdictional management, and licensing.

Dr. Laura Harman Chief Scientific Officer
PhD in Viral Immunology, University of Cambridge. Extensive R&D experience in diagnostics, vaccines, and anti-infectives. Leads the scientific function at IP3T, with a focus on innovation that bring significant economic and environmental benefit.

Key Risks & Mitigations

  • Patent Litigation: Mitigated via IP insurance and proactive enforcement strategy
  • Infringement & Royalty Evasion: Enforced via robust legal clauses and 3rd-party audit rights
  • Regulatory Delays: Factored into timeline models with conservative assumptions
  • Licensing Delays: Multiple licensees per asset minimize timing risk

 

  Operational, funding, and macro risks covered in general risk section.

Market Opportunity

ESG impact highlights by innovation:

 

PATHOSTOP:PROTECTIONHEALTH 

SKOSHMARK:SECURITYREGULATORY

AIVIBA:HEALTHPHARMACEUTICAL

HIPPOPAK:SUSTAINABLELOW CARBON FOOTPRINT

INSUHEDRA:INSULATIONCARBON CAPTURE

SPECIDENT:IDENTIFICATIONENVIRONMENT

RECHECKA:REGULATORYQUALITY ASSURANCE

 

IP3T innovates for the realization of a sustainable future – optimizes the environmental, financial and societal value of every innovation, supporting our licensees sustainability, decarbonisation and ESG goals.

Market highlights by sector:

 

 

MATERIALS SCIENCE – research and development of new materials

MATERIALS ENGINEERING – engineering solutions using new materials

MATERIALS TECHNOLOGY designing application processes, software and systems

Licensing, Pipeline & Traction

  • IP3T licensing team has decades of experience, including running a Big Four Global IP Advisory practice.
  • Have a proven track record of delivering substantial value to a wide range of clients, from multinational FTSE100 and Fortune500 companies to SMEs and academic institutions.
  • Successfully served clients across various industries, including TMT, Financial Services, Life Sciences & Healthcare, Automotive, and Energy, Resources & Industrials
  • Have developed a global network of IP Buyers, IP Sellers and IP Investors

IP portfolio lifecycle

 

Timeline for projected license signings and revenue ramp-up

 

Royalty rate, market penetration & maturation per IP asset:

PROJECTED NET REVENUE & MATURATION (BY IP ASSET)

Royalty Ranges

Across 14 industries, reported royalty rates generally fall between 25 percent of the operating margins and 25 percent of the gross margins (the 25% rule). In other words, 25 percent of gross margin serves as an upper bound for the reported rates, while the 25 percent of EBIT margins provides a lower bound. (Chart 1)

The reported royalty rates account for 15 percent, 41 percent, and 53 percent of gross, EBITDA, and EBIT margins, respectively.

Chart 2, takes a closer look at net sales, the most widely used base. In 2010 the average annual royalty rate peaked at just over 15%, before dropping in 2014, at nearly 9%. Since then, the annual royalty rate has climbed steadily and sits at 13.2% for 2016.

Learn More About IP3 Technologies

Thank you for your interest in IP3 Technologies.

Please fill out your information and we will contact you shortly with more information on this opportunity.

0 Comments

Leave a reply

Your email address will not be published. Required fields are marked *

*

CONTACT US

Hi. We're not around right now. But you can send us an email and we'll get back to you, asap.

Thanks, Ken

Ken Margolis | Managing Partner Castle Placement, LLC
1460 Broadway Street, Rte 400
New York, New York 10036
(212) 418-1188 | C: (516) 712-7784
kmargolis@castleplacement.com

Sending
42513